At Equillium, we leverage deep understanding of immunology and its role in disease to pioneer new products for severe autoimmune and inflammatory disorders.
Itolizumab is being developed in multiple severe immuno-inflammatory diseases.
Clinical trials in acute Graft-Versus-Host Disease (aGVHD), asthma, and SLE / lupus nephritis are actively enrolling patients.
FDA fast track designation for itolizumab demonstrates that targeting CD6 may address the high unmet therapeutic need for lupus nephritis patients.
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
Our EQUALISE study is now enrolling people with lupus or lupus nephritis.
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
Bringing treatments designed to restore the balance of the immune system to patients who hope to restore the balance in their lives.
Equillium is actively recruiting individuals to participate in clinical trials for acute graft-versus-host disease (aGVHD), uncontrolled asthma, and lupus nephritis.